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1. Introduction 
Systemic lupus erythematosus (SLE), which is an inflammatory disease of unknown cause, 
is a representative autoimmune disease. Although SLE has multisystem organ involvement 
with a predilection for females, the disease varies from mild to severe and/or from active to 
inactive. The severity and activity of the disease affect SLE prognosis [1]. 
Glucocorticosteroids (steroids) have anti-inflammatory and immunosuppressive effects, 
although the biological effects of steroids are multiple. The anti-inflammatory effect of 
steroids is powerful and acts rapidly, and the immunosuppressive effect after 
administration of large doses of steroids is also strong. Therefore, steroids play a major and 
essential role in the treatment and management of SLE patients, especially those having 
severe and active SLE. However, the effectiveness and usefulness of steroids are limited 
because of their severe side effects, unresponsiveness and resistance to steroids. In these 
situations, additional therapies such as immunosuppressive agents or plasmapheresis, etc. 
are usually used in conjunction with steroids. 
This paper will present clinical data related to steroid therapy from 1,125 patients with SLE 
who were examined and treated in Juntendo University Hospital between 1955 and 2002. It 
will show the benefits and risks of treatment with steroids and/or combined therapy with 
steroids and immunosuppressants. 
2. Clinical presentation of 1,125 patients with SLE 
2.1. Clinical findings  
One thousand one hundred and twenty-five SLE patients fulfilling four or more of the 
revised ACR (American College of Rheumatology) criteria [2] were examined and treated at 
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the Department of Internal Medicine and Rheumatology in Juntendo University School of 
Medicine between 1955 and 2002. In all patients, the diagnosis and treatment procedures 
were conducted during a period when the use of steroids and immunosuppressive agents 
was common. Computerized analysis of clinical manifestations, laboratory and 
immunological findings, treatments, complications, causes of death and prognosis was 
conducted. 
The distribution of age at diagnosis and the difference in gender, showing that mean age at 
diagnosis was 27.1 years old and the male to female ratio was 1:9. In children and adults 
over the age of 50, the incidence of SLE demonstrated only a slight female predominance, 
however, for those in their twenties, thirties and forties, close to 90% of patients were 
women. The frequencies of major clinical manifestations and laboratory findings from 
observations together with the data from other investigators [3-6] are shown in Table 1.  
Table 1. Cumulative percentage incidence of clinical and laboratory manifestations in SLE 
2.2. Treatment according to disease severity  
Clinical subsets of SLE were divided into three groups according to disease severity that 
related to prognosis [7]. They were severe, moderate and mild diseases. Severe disease 
included organ-threatening conditions: lupus nephritis; rapidly progressive 
glomerulonephritis (RPGN), diffuse proliferative glomerulonephritis (DPGN), nephrotic 
syndrome, neuropsychiatric lupus (NPLE); acute confusional state or organ brain syndrome, 
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while pulmonary manifestations included acute lupus pneumonitis, alveolar hemorrhage, 
etc. Moderate disease: lupus nephritis without renal failure, pleuritis, pericarditis, 
meningitis, hemolytic anemia, thrombocytopenic purpura, etc. Mild disease: 
arthralgia/arthritis, myopathy, skin rash, etc. 
 
PSL ≦39mg/day was used for patients with mild or moderate diseases. 
PSL 40-59mg/day was used for patients with moderate or severe diseases. 
PSL ≧60mg/day was used for patients with severe diseases. Pulse therapy was used for patients with severe diseases 
followed by large doses of steroids. 
Table 2. Treatments of 1125 SLE patients 
Treatments including steroids and immunosuppressive agents are shown in Table 2. 
Steroids were a mainstay of treatment for SLE. Although there are several kinds of steroids, 
prednisolone (PSL) is commonly used to treat SLE. The initial dose of steroids was usually 
determined according to the severity and activity of the disease. The above severe diseases 
required large doses of steroids usually of 1 mg/kg/day of PSL or more. Sometimes steroid 
pulse therapy (methylprednisolone 0.5-1g/day, intravenously administration, for 3days) was 
used followed by large doses of steroids. The above moderate to mild diseases usually 
required 0.5-1mg/kg/day and less than 0.5mg/kg/day of PSL, respectively. When a 
satisfactory response was achieved, the daily dose was reduced by 5 to 10% over 2 or 3 
weeks until reaching a maintenance dose of 0.2 to 0.3mg/kg/day. 
Steroids have sometimes little or no effect because of impaired bioavailability due to 
reduced steroid absorption, increased steroid metabolism, induction of activating protein 
1(AP-1) which is mutually antagonistic with steroid receptors for trans-activation effects [8], 
and insensitive steroid-mediated apoptosis of T cells [9], etc. Furthermore, steroids 
characteristically have a high risk of serious side effects such as infection, gastric ulcer, 
diabetes mellitus, osteoporosis, etc. Therefore, the effectiveness and usefulness of steroids 
were limited because of severe side effects, unresponsiveness and resistance to steroids. In 
Nonsteroidal anti-inflammatory drugs
Steroids (initial dose of steroids) (n=1125)
no
PSL ≦ 39mg/day
PSL 40-59mg/day
PSL ≧ 60mg/day
Pulse therapy
Immunosuppressants
azachioprine
6-mercaptoprine
cyclophosphamide
mizoribin
others
Plasmapheresis
Hemodialysis
800/1125 (71%)
99 (  9%)
769 (68%)
133 (12%)
124 (11%)
171 (15%)
300/1125 (27%)
160 (53%)
26 (  9%)
70 (23%)
32 (11%)
12 ( 4%)
105/953 (11%)
25/1125 (  2%)
PSL:prednisolone
thioprine
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these situations, immunosuppressive agents such as cyclophosphamide, azathioprine, 
mizoribine, tacrolimus and/or plasmapheresis or other innovative therapies were usually 
used in conjunction with steroids. Recently, belimumab (anti-BLyS antibody), the first 
targeted biological drug, was approved for treatment of SLE by the FDA [10]. Targeted 
biological and small-molecule therapies in SLE are going to begin to take the place of 
steroids that have been used as the major drug in SLE for more than 50 years. 
2.3. Prognosis and causes of death 
In this paper, the survival rate was 93% at 5years, 89% at 10years and 69% at 20years after 
diagnosis. One hundred and fifty-one out of 1,125 patients (13%) died. The causes of death 
were renal failure (30%), cerebrovascular diseases (23%), infection (19%), and others. 
Infections which led to causes of death included sepsis or bacteremia due to E. coli, 
methicillin resistant Staphylococcus aureus (MRSA), candidiasis, asprgilosis, Klebsiella, 
Pseudomonas, etc., and tuberculosis, pneumocyctis carini pneumonia, Cryptococcus 
meningitis, listeria meningitis, cytomegalovirus infection, etc. In the last 2 or 3 decades it has 
been noted that the prognosis of SLE has improved [11-13]. Changes in the mortality rate in 
accordance with the cause of death in SLE patients were also observed, showing a 
significant reduction in death due to renal failure.  
3. Steroid therapy in principal organ involvement in SLE 
3.1. Lupus nephritis (LN) 
3.1.1. Clinical analysis of LN 
LN is one of the diseases influencing the prognosis of SLE. The diseases of LN vary from 
mild to severe and from active to inactive. The clinical pictures of LN and the types of the 
World Health Organization (WHO) classification according to histopathological findings 
[14] in this study are shown in Table 3.  
Persistent proteinuria of more than 0.2g/day and less than 3.5g/day was observed in 
approximately 37% of cases and profuse proteinuria of more than 3.5g per day was 
observed in approximately 17% of cases. Patients without proteinuria accounted for 16%. 
Abnormal urinary sediments including erythrocytes, leukocytes and casts were observed 
frequently. An increasing serum creatinine level was observed in 41% of cases. The WHO 
classification according to histopahological findings of LN by renal biopsy was used in this 
study, although the classification of LN by the International Nephrology/Renal Pathology 
Society (ISN/RPS) was proposed in 2003[15]. Diffuse proliferative glomerulonephritis 
(DPGN) of Type IV, which has a poor prognosis, could be seen in 55 of 216 cases (25%), 
which underwent renal biopsy. Membranous glomerulonephritis (MGN) of Type V 
characteristic of nephrotic syndrome, was observed in 18% of cases. Types I and II, which 
are thought to have better prognosis, were observed in 23% and 16% of cases, respectively. 
Advanced Type VI, which indicates end stage GN, could be seen in 12% of cases.  
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Table 3. Lupus nephritis in 1125 cases 
3.1.2. Treatment of LN 
The available therapeutic procedures include steroids, immunosuppressive agents, 
plasmapheresis, anticoagulants and hemodialysis, etc. Steroids were the first choice for 
treatment of LN. However, doses of steroids were determined according to urinary findings, 
renal function and renal histopathological findings evaluating the activity and severity of 
LN. The patients with active and /or severe LN, including persistent or profuse proteinuria, 
renal dysfunction, DPGN of type IV, rapidly progressive glomerulonephritis (RPGN) or 
MGN of Type V in conjunction with low serum complement levels and high titers of anti-
dsDNA antibodies, were initially treated with large doses of steroids (PSL 1-1.5mg/kg/day) 
as induction therapy for remission. Steroid pulse therapy was often administered at first. It 
led to more rapid recovery which might be result of a rapid nongenomic physicochemical 
effect. The patients with intermittent proteinuria, abnormal urine sediments, and Type II or 
III, were initially treated with PSL less than 0.5-1mg/kg/day. After PSL administration for 3-
6 weeks, the dosage of PSL was then reduced by nearly 10% every 2–3 weeks according to 
the improvement in proteinuria, urinary sediments, abnormal renal function, low serum 
complement levels and high titers of anti-dsDNA antibodies. If PSL had no or incomplete 
response, the dosage was increased by 20% or steroid pulse therapy was conducted again. In 
the patients with DPGN or RPGN, intravenous pulse therapy of cyclophosphamide (IVCY) 
(500-750mg, monthly for 3 to 6 months), as immunosuppressive agent, was used. 
Alternative induction therapies included combined therapies with steroids and 
immunosuppressive agents such as daily oral cyclophosphamide, azathioprine, tacrorimus, 
mizoribine, and cyclosporine, etc. If an incomplete response after 2 months treatment with 
A. Urinalysis, Renal function
No proteinuria
Proteinuria
Intermittent 
Persistent 
Profuse (>3.5g/day) 
Microhematuria
Urine casts
Elevated BUN 
Elevated S-creatinine
n=1125
176
949
431
354
164
1066
838
659/1063
429/1047
(%)
(16)
(84)
(45)
(37)
(17)
(95)
(74)
(62)
(41)
B. Histopathological findings (WHO classification) 
I. Minimal change (MC) or Normal                       
II. Mesagial alteration
III. Focal segmental glomerulonephritis (FGN)
IV. Diffuse proliferative glomerulonephritis (DPGN)
V. Membranous glomerulonephritis (MGN)
VI. Advanced                                          
n=216
49
34
35
55
39
4
(%)
(23)
(16)
(16)
(25)
(18)
(12)
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PSL alone was also observed, immunosuppressant agents were administered in addition to 
PSL. If the patients had high titers of anti-dsDNA antibodies and/or immune complexes, 
plasmapheresis was conducted in conjunction with the above steroid and 
immunosuppressant agent treatment. In patients who achieved remission showing less than 
0.5g/day of proteinuria, inactive urine sediment, normal complement levels and /or 
quiescent extrarenal lupus activity, they continued maintenance treatment with a 
maintenance dosage of steroids of PSL 5–15mg/day. Thereafter, the PSL dosage was tapered 
to discontinuance in an extremely gradual manner.  
3.1.3. Outcome and prognosis of LN 
During the past half century, the prognosis of SLE has significantly improved. One of the 
major factors in this improvement is the significant reduction in renal death. This is 
assumed to be partially due to early diagnosis and early treatment with the development of 
diagnostic procedures, as well as the development of treatments including the 
implementation of hemodialysis [1,11-13]. However, the remission rate of lupus nephritis 
was not so high.  
 
Figure 1. Remission rate of lupus nephritis according the WHO classification type and degree of 
proteinuria 
Figure 1 shows the remission rate after onset according to the WHO classification type and 
degree of proteinuria. The remission rates of patients with Type IV (DPGN) and profuse 
peroteiniria or nephrotic syndrome tended to decrease during the course of the disease, 
while the remission rates of patients with Type II and persistent proteinuria tended to 
increase. Patients with Type V (MGN) had a low remission rate through out the course of 
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the disease, but no decrease in the remission rate was observed until later on. Furthermore, 
in the outcome of 32 patients who were treated over the long-term for over 20 years, the 
complete remission rate was 27%, the incomplete remission rate was 37.8%, and the 
worsening rate was 21.6 %. As for the treatments used, those that contributed to remission 
could not be specified. This fact suggests that the underlying disease types had a greater 
influence on the remission rate than the treatment method.  
3.2. Neuropsychiatric manifestations of SLE (NPLE) 
3.2.1. Clinical analysis of NPLE 
The frequencies of various neuropsychiatric manifestations of SLE (NPLE) have been 
reported to vary from 28 to 59%. In our study, NPLE could be observed in 47.6% of 1,125 
cases as shown in Table 4.  
 
Table 4. Frequencies of neuropsychiatric manifestations (NPLE) in 1125 lupus patients 
The American College of Rheumatology (ACR) proposed new criteria for the classification 
of neuropsychiatric syndrome of systemic lupus erythematosus (NPSLE) in 1999 [16]. NPLE 
is divided into psychiatric and neurological manifestations. The frequency of psychiatric 
manifestations was higher than that of neurological manifestations. The former included 
acute confusional state or organ brain syndrome, cognitive dysfunction, anxiety disorders 
and psychosis, etc., while the latter included seizure, cerebrovascular disease, myelopathy, 
aseptic meningitis, headache, and peripheral neuropathy, etc. 
Although no single pathogenetic process could explain all these manifestations, it was 
assumed that other potential causes of these manifestations, such as side effects from 
treatment, complications including infections, etc., had been excluded except for causes due 
to lupus itself. Many NPLE cases were considered to be caused by lupus itself, excluding 
obvious causes such as antiphospholipid antibody syndrome (APS), necrotizing angiitis, 
and complications. 
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NPLE is one of the diseases that influence the prognosis of SLE as well as LN. Especially, 
patients with acute confusional state or organ brain syndrome (OBS), cognitive dysfunction, 
recurrent seizure, and cerebrovascular disease, etc., had poor prognosis. Acute OBS exhibits 
characteristic malfunctions such as consciousness disorders (i.e. delirium), disorientation, 
memory disorders, and cognitive dysfunction. Acute OBS showed an 85% correlation with 
SLE activity and exacerbation, which was greater than that of the psychiatric illness group 
(57%) and the psychosyndrome group (23%) [17]. 
Although acute OBS was correlated with active SLE lesions, correlations with high titers of 
anti-dsDNA antibodies and low complement levels, which were seen in active LN, were not 
necessarily observed. Serologically, acute OBS correlated with the serum anti-liposomal P 
antibody, interferon α and IL-6 in cerebrospinal fluid (CSF) [18-19]. 
On the other hand, acute neurologic syndrome has been reported to correlate with the anti-
asialo GM1 antibody, anti-liposomal P antibody, anti-lymphocyte antibody, and anti-
neurocyte antibody, as well as the anti-PCNA antibody and anti-Sm antibody [7,20]. 
Psychiatric symptoms often required differentiation from steroidal psychiatric symptoms. 
Differentiation from secondary psychiatric symptoms due to uremia and/or infection was 
also important. Although quite a number of cases were difficult to determine, the following 
information might have been helpful:  
a. The actual incidence of steroid-induced psychosis is small, probably about 5%, which is 
less than that of lupus-induced psychosis [21]. 
b. The psychiatric side effects of steroids include, most commonly, mild to moderate 
mood changes such euphoria, sleeplessness, or depression rather than unconsciousness 
disorders, although there are also perceptual changes, hallucinations, anxiety, insomnia 
and confusion.  
c. Steroid-induced psychosis appears half a month to one month after administration of 
steroids. It has been reported that the incidence of steroid-induced psychosis increases 
when over 40mg/day of PSL is administered [22].  
d. Although lupus psychosis may not always be improved by increasing of the dosage 
of PSL, deterioration of lupus psychosis after increasing the dosage of PSL is rare. 
e. High levels of IgG index and IL-6 in CSF can be seen in lupus psychosis [23]. 
The evaluation of NPLE should always include an assessment of whether SLE is active or not. 
In addition, patients with both focal and diffuse syndromes should have various examinations 
including CSF, electroencephalogram (EEG), and an imaging studies (such as computed 
tomography (CT) and magnetic resonance imaging (MRI)), cerebral blood flow by angiography 
or single photon emission computerized tomography (SPECT), etc. The more serious the NPLE, 
the more aggressive immunosuppressive therapy, including steroids, is needed. 
3.2.2. Treatment of NPLE 
If NPLE was active and there was severe major organ involvement, steroid therapy was 
indicated. In particular, patients with an acute confusional state or organic brain syndrome, 
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and recurrent convulsive seizures were treated with high steroid doses (PSL l–2 mg/kg/day) in 
conjunction with steroid pulse therapy. However, when improvement could not be seen 
within 48 hours after treatment, 250 to 500mg of hydrocortone was administered every 12 
hours. If improvement could not be seen after treatment of steroids alone, IVCP pulse therapy 
or oral administration of CP in conjunction with steroids and/or plasmapheresis was given. 
When signs of clinical manifestations were stable for more than 6 weeks and acute phase 
reactants or tests of organ function were improved or stable for 6 weeks, the dose of PSL 
was reduced by approximately 10 to 20% every two weeks. When the dose of PSL reached 
about 15mg/day, it was slowly tapered and reduced by 1mg every week.  
When the patients showed panic or marked agitation and their hallucinations and delusions 
were threatening, several antipsychotic drugs in conjunction with steroids were also used.  
3.2.3. Outcome and prognosis of NPLE 
Almost all patients with NPLE improved after immunosuppressive therapies including 
steroids, immunosuppressive drugs and /or plasmapheresis.  
 
 
Figure 2. The clinical course of SLE patient (46 years old, female) with organic brain syndrome (OBS) 
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Figure 2 shows the clinical course of an SLE patient with OBS who was a 46-year old female. 
She was diagnosed as SLE with malar rash, eruption, leucopenia, thrombocytopenia, 
proteinuria and positive anti-nuclear antibodies, etc. in March 1997. In April 1997, she had 
recurrent unconsciousness with delirium, disturbance of articulation with high fever and a 
worsening malar rash. Although anti-DNA antibodies and low complemetemia could not be 
seen, she was diagnosed as OBS or acute confusional state and treatment with steroid pulse 
therapy followed by a PSL dose of 80mg/day. Plasmapheresis was also conducted to remove 
anti-lymphocyte antibodies. Although mood disorder and depression were observed in 
August, 1997, her disease improved without increasing doses of steroids or additional 
treatment with immunosuppressive agents. 
As for prognosis of lupus patients with NPLE according to the different treatment, patients 
treated with combined therapy of steroid pulse therapy and other therapies was 
significantly more favorable than those treated with steroids alone (PSL>40mg/day) and 
those treated with combined therapy of immunosuppressive agents and steroids. 
3.3. Pulmonary manifestations 
3.3.1. Pleuritis 
Pleuritis is by far the most common pulmonary manifestation, occurring at some time in the 
course in 40 to 50% of lupus patients. However, the frequency of pleuritis in Japanese SLE 
patiens was lower than that in European countries and the United States. The frequency of 
pleuritis was 11% in this study. . Clinically, fever, chest pain, cough, dyspnea etc. could be 
seen in patients with pleuritis. On chest X-rays, slight to moderate pleural effusion caused 
by pleural inflammation could be observed bilaterally in approximately half of cases.  
Pleuritis mostly improved after administration of PSL (20-40mg/day). However, in cases 
with a large amount of pleural effusion , thoracic drainage was needed.  
3.3.2. Interstitial pneumonitis 
Lupus pneumonitis is classified as acute lupus pneumonitis and chronic interstitial 
pneumonitis/pulmonary fibrosis. Acute lupus pneumonitis was relatively rare with an 
occurrence of 0.5–11.7% [24-25]. It was observed in 6 of 1,125 patients (0.5%) in this study. 
As clinical symptoms, fever, chest pain, dry cough, severe dyspnea, and occasional 
hemoptysis were noted. Bibasilar Velcro rales were noted in all instances. The majority of 
patients were hypoxic, requiring supplemental oxygen or intubation for assisted ventilation. 
Acute lupus pneumonitis was diagnosed by several examinations including X-ray, CT scan, 
KL-6 and/or SP-D as biomarkers, and various kinds of infectious examination to exclude 
infectious diseases.  
All 6 patients with acute lupus pneumonitis were treated with steroid pulse therapy 
following 1-2mg/kg/day of PSL. Half of the patients drastically improved, but the remaining 
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3 patients died of pulmonary hemorrhage despite combined therapy with steroid and 
immunosuppressant agents and /or plasmapheresis. 
Chronic interstitial pneumonitis in SLE is also rare, showing a low frequency of 3-5%. Six 
patients with chronic interstitial pneumonitis were observed in this study and they were 
treated with maintenance therapies including low doses of steroids and/or 
immunosuppressant agents. In one patient, chronic interstitial pneumonitis deteriorated to 
acute interstitial pneumonitis during the course of the disease and a large dose of steroids 
was needed 
3.3.3. Alveolar hemorrhage 
Alveolar hemorrhage in SLE is relatively rare, and it has been reported to occur in 1.4–1.7% 
of SLE patients in Europe and the United States [26].  
It is a serious complication and results in poor prognosis. It was observed in 8 out of 1,125 
patients (0.7%) in this study.  
SLE patients with alveolar hemorrhage had hemoptysis and hypoxemia and rapid 
progression of anemia in conjunction with active LN and/or NSLE disease.  
All patients with alveolar hemorrhage were treated with steroid pulse therapy following large 
doses of PSL, but it was also necessary to concomitantly use other immunosuppressive 
tharapies such as cyclophosphamide including IVCY, and plasmapheresis. Unfortunately, all 
of the patients with alveolar hemorrhage died, comfirming that the prognosis was very poor. 
3.4. Cardiac manifestations 
3.4.1. Pericarditis 
The most common cardiac abnormality was pericarditis, which occured in 8-25% [27], but it 
was relatively rare in Japan, with a frequency of 7% (47 out of 1,125cases) in this study. 
Pericarditis is often one of the first manifestations. Most of the cases with pericarditis 
improved with administration of PSL 0.5–1 mg/day, but cases with cardiac tamponade, 
which was rare in this study, needed large doses of PSL over 1mg/day and/or steroid pulse 
therapy. 
3.4.2. Myocarditis 
Myocarditis was rarely observed in 2% in this study. In cases with myocarditis, positive 
CRP, elevated CK, IgG class anti-dsDNA antibodies, hematuria, etc., in conjunction with 
tachycardia, cardiac enlargement, congestive heart failure could often be observed. A 
myocardial biopsy was performed in order to confirm the diagnosis in one patient. The 
patients with myocarditis associated with congestive heart failure were treated with large-
dose administration of steroids (PSL l–1.5 mg/kg/day, divided into 3~4 dosages). All of the 
patients with myocarditis improved after steroid therapy. 
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3.4.3. Myocardial infarction and coronary artery disease 
Coronary artery disease due to arteriosclerotic changes is more common in SLE patients. 
Death from myocardial infarction late in the course of the disease is one of the most frequent 
causes of death after 10 to 30 years of SLE [28]. Eleven lupus patients with myocardial 
infarction could be seen in this study. The average age at diagnosis of SLE was 37 years old 
(26–63 years old), and the average age at development of myocardial infarction was 51 years 
old (41–66 years old) in these patients. There were two death cases, including one case of 
death from cardiac rupture. 
Several risk factors that cause myocardial infarction due to atherosclerosis in SLE are 
considered. They are renal involvement, hypertension, hyperlipidemia, long-term 
administration of steroids, diabetes mellitus, anti-phospholipid syndrome, smoking, etc. In 
this study, 4 patients had hypertension, hyperlipemia and diabetes mellitus as risk factors. 
Furthermore, positive antiphospholipid antibodies were observed in 5 cases. Death from 
myocardial infarction due to inflammation of the coronary arteries has been reported in SLE 
patients dying early in the course of their disease, but this is a rare event [28].  
Regarding the treatment in this study, conservative medical management without large 
doses of steroids was used in most cases. PTCA and AC bypass procedures were also 
occasionally conducted. 
3.5. Intestinal vasculitis 
Acute abdomen caused by intestinal vasculitis is often observed. Occasionally, surgery is 
needed. According to a report by Zizic, et al. [29], acute abdomen was observed in 15 of 140 
cases, and caused death in 53% of cases. Vasculitis was observed in 9 of 11 cases with 
abdominal surgery, and intestinal perforation was observed in 6 cases. In this study, 4 
patients had intestinal vasculitis and 3 died of intestinal perforation. Intestinal bleeding and 
peritoneal bleeding due to vasculitis were often observed. In cases with mesenteric arteritis, 
acute abdomen with severe abdominal pain in conjunction with nausea/vomiting, diarrhea, 
ascites, gastrointestinal bleeding, and fever, etc., were observed. Those symptoms may be 
masked by steroids or immunosuppressive drugs used for treatment, thus resulting in a 
delayed diagnosis. 
Patients with intestinal vasculitis and/or mesenteric arteritis were treated with large dose 
steroids including steroid pulse therapy.  
When a rapid improvement was not obtained, intermittent IVCY therapy was 
simultaneously used. In cases associated with bowel infarction or perforation, treatment for 
infection was also needed.  
3.6. Hematologic manifestations 
Hematologic manifestations in SLE include normochromic-normocytic anemia caused by 
chronic inflammation, autoimmune hemolytic anemia (AIHA), iron-deficiency anemia, 
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leukocytopenia, lymphocytopenia, thrombocytopenia, thrombocytopenic purpura (TP), 
thrombotic thrombocytopenic purpura (TTP), and antiphosphlipid syndrome (APS), etc. 
The diseases, which needed high doses of steroids were AIHA, TP, and TTP. 
3.6.1. AIHA 
AIHA was observed in 11% of patients in this study. AIHA is rare in Japanese SLE patients 
in comparison to those in Europe and the United States. Steroids were the mainstay of the 
treatment for AIHA and a response was achieved in about 75% of patients. PSL was given 
initially at a dose of 1.0 to1.5mg/kg and continued at that level for at least 4 to 6 weeks. 
Following a satisfactory response, the dose was reduced gradually by 10% every week. The 
reticlocyte count was a reliable indicator of both responsiveness to treatment and relapse. In 
cases of severe fulminant hemolysis, steroid pulse therapy was conducted. Patients with 
AIHA who failed to respond to steroids were treated with immunosuppressant agents 
and/or splenectomy. Plasmapheresis, high-dose intravenous gammagloburin therapy (IVIg), 
and danazole were also used for some refractory cases. 
3.6.2. TP 
Thrombocytopenia lower than 150,000 was observed in 34% of cases in this study. However, 
thrombocytopenia lower than 50,000 was relatively rare, and it occured in approximately 
10% of cases. Thrombocytopenia in SLE is usually due to antiplatelet autoantibodies 
(platelet associate-IgG; PA-IgG, platelet binding-IgG; PB-IgG). In some cases, 
thrombocytopenia was associated with antiphospholipid antibodies. In rare case, so-called 
Evans syndrome, in which AIHA and TP coexist, was observed. Some cases did not tend to 
bleed until platelet counts were less than 20,000/ul. Patients with thrombocytopenia less 
than 20,000 were treated with large doses of steroids. The initial dose of PSL was usually 1-
2mg /kg/day. After an increase in platelet count occurred in response to steroids, the dose 
was gradually reduced after 4 weeks. If thrombocytopenia did not respond to steroids with 
bleeding from the major organs such as gastrointestinal tract, kidney, bladder, other 
mucosal surface, steroid pulse therapy was used. IVIg was useful to achieve a temporary 
improvement in thrombocytopenia in surgical operations such as splenectomy, which was 
often conducted in steroid resistant cases. .In steroid resistant cases, immunosuppressive 
drugs such as azathioprine, cyclophosphamide, and cyclosporine, danazol, and vincristine, 
etc., were also used.  
3.6.3. TTP 
TTP usually consists of a pentad of TP, microangiopathic hemolytic anemia, fever, renal 
failure, and neurologic manifestations. TTP has been reported in association with various 
other diseases, including SLE, most of which are characterized by some degree of vasculitis 
of the small vessels and circulating immune complexes [30]. The main cause of acquired TTP 
including SLE is assumed to be an autoantibody that is an inhibitor (IgG inhibitor) of von 
Willebrand factor cleaving protease [31]. It has been clarified that congenital TTP is caused 
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by a mutation in the ADAMTS-13 gene of cleaving protease. TTP must be differentiated 
from DIC or catastrophic antiphospholipid syndrome, but coexistence of both are often 
observed.  
Regarding treatment, plasmapheresis using fresh frozen plasma, and transfusion therapy of 
normal plasma are used. In addition, large-doses of steroids including steroid pulse therapy, 
immunosuppressive drugs, IVIg therapy, and anti-platelet drugs, etc. are simultaneously 
used. 
3.7. Pregnancy and birth 
When an SLE patient wished to conceive and give birth, a medical determination as to 
whether pregnancy would be possible was considered. Basically, there were presumed to be 
almost no problems in pregnancy when the patient was in remission with a maintenance 
dosage of steroids, and when serious organ failure was not observed. Moreover, even if the 
patient had active disease, pregnancy was allowed after the disease improved with 
treatment.  
3.7.1. Treatment and management during pregnancy  
It was important for the physician and the gynecologist to be in close communication for the 
treatment and management during pregnancy. Usually, it was unnecessary to change the 
maintenance dose of the steroid during pregnancy. When mild deterioration was observed 
in the early stage of pregnancy, an increased steroid dosage was attempted according to the 
clinical manifestations. If the clinical manifestations required administration of a large-dose 
of steroids, considering the risks to the mother and the effect of the steroids on the fetus, an 
artificial abortion was performed at an early stage. Although the level of serum cortisol in 
the fetus decreases during the steroid administration, cortisol secretion and response to 
ACTH are believed to remain normal [32]. If a mother is treated with prednisolone or 
hydrocortisone, these steroids are assumed to have a minimal effect on the fetus because 
they are inactivated by 11-β-dehydrogenase in the placenta. However, the use of 
dexamethasone and betamethasone is avoided because these steroids are difficult for the 
enzyme to inactivate and were assumed to have an adverse effect on the fetus. 
3.7.2. Treatment and management during and after deliverly 
3.7.2.1. Prevention of exacerbation 
The mother was hospitalized prior to the expected delivery date for management of the 
mother and fetus. If pregnancy remained steady, and SLE activity was not observed, the 
dose of steroids was increased immediately after delivery to prevent any exacerbation of 
SLE. The dose of steroids was usually increased to two or three times the pre-delivery dose. 
The dose was reduced by 10% every 4 to 7 days while confirming no exacerbation, and 
continually observed until eventually reducing it to the dosage at the time of delivery. If an 
exacerbation of SLE such as active LN or serositis was observed in the late stage of 
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pregnancy, the delivery of the fetus was attempted as early as possible in order to start 
treatment of the mother’s clinical manifestations. 
3.7.2.2. Breast-feeding  
Because the amount of steroids was increased upon delivery, breast-feeding was prohibited 
until the dose was reduced to less than 20 mg of PSL, considering the rate of transfer of 
steroids (0.1–0.3%/day) to the mother’s milk [33]. 
3.8. Adverse effects and complications due to steroid treatment 
Side effects of prolonged treatment with oral steroids are well known. Changes in the 
physical appearance could usually be seen. They were acne, hirsutism, moon face, buffalo 
hump, obesity, and abdominal striae, etc. Although reversible with a discontinuation or 
reduction in dose, hypertension, peptic ulcer, diabetes mellitus, pancreatitis, osteoporosis, 
psychosis, etc. were also induced. Thinning of the skin, cataracts, glaucoma, osteoporosis, 
and osteonecrosis could be observed as irreversible side effects.  
Infections were major complications in SLE and one of the major causes of death. 
Susceptibility to infection, particularly bacterial infection, was increased with steroid use. 
Staples et al. found that the infection rate in hospitalized patients increased from 0.43 to 1.63 
per 100 hospital days with an increase in steroid dose from zero to more than 50mg/day [34]. 
Although infection rarely occurs with a small dose of PSL (2–10 mg/day), the SLE patients 
treated with PSL of more than 20mg/day have a higher risk of infection due to the higher 
dose of PSL, especially after 14 days of administration. PSL was also noted to be a major risk 
factor for the development of opportunistic infection, with the most common organisms 
including Salmonella, Candida, Strongyloides, and Aspergillus.sp according to a case 
controlled study of 797 SLE patients [35]. 
It has been noted that systemic administration of steroids could be linked to the higher 
occurrence of vascular diseases such as coronary artery disease, stroke, peripheral vascular 
disease than the expected occurrence in SLE. However, it is unclear whether this reflects 
pro-atherogenic effects of the underlying disease process or adverse metabolic effects 
associated with steroid use [36]. Recently, the number of patients with complications such as 
myocardial infarction/angina pectoris, cerebral infarction, diabetes mellitus, hypertension, 
and aseptic bone necrosis, has tended to increase over a long-term observation period due to 
a favorable SLE prognosis.  
Table 5 shows the frequencies of these complications at the time of occurence in 97 SLE 
patients who had been observed for over 20 years. The number of patients with myocardial 
infarction/angina pectoris, diabetes, cerebral infarction increased from the ninth year of the 
observation period. Hypertension and aseptic osteonecrosis were seen from the onset of 
SLE. Most of the above complications were thought to be due to treatment including 
steroids, as well as aging. It was also noted that GC-associated damage accumulated over 
time to constitute most of the damage at 15 years, although disease –activity related damage 
occurred early [37]. 
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Table 5. Frequencies of complications related to vascular diseases according to the year (s) of the 
occurrence in 97 SLE patients who had been observed for over 20 years 
Steroid use contributes significantly to risk of osteoporosis in women with SLE. Ramsey-
Goldman et al. surveyed the frequency of fractures and associated risk factores in702 
women with SLE who had been followed for 5951 person-years and found that fractures 
occurred in 12.3% of patients, an almost fivefold increase compared with a background 
population [38]. Older age at diagnosis and longer duration of steroid use were 
important valuables. Sinigaglia, et al. reported that osteoporosis in 22.6% of 84 
premenopousal patients with SLE according to bone mineral density (BMD) was 
observed, and both disease duration and glucocorticoids were associated risks [39]. 
Steroid–induced osteoporosis leading to fracture, particularly vertebral collapse, was a 
major problem.  
Aseptic osteonecrosis (AON) was observed in approximately 10% of SLE, with the 
femoral head being a common site. It also appeared in the femoral condyle, caput 
humeri, proximal end and distal end of the tibia, etc.. It has been suggested that 
increased doses of steroids (especially in the first year of treatment) and the duration of 
steroid therapy are correlated with a grater risk of AON in SLE patients [40]. In a 
prospective survey of SLE patients with administration of high-dose steroids (more than 
30 mg/day of PSL for more than one month), AON occurred in 15% (9/62 patients) and 
the average period from the administration of a large dose of steroids to onset of AON 
was 640 days [41].  
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4. Conclusion 
In this paper, steroid therapy for SLE based on the clinical analysis of 1,125 cases, especially 
for principal organ involvement that required large doses of steroids, was evaluated. 
Although there is no doubt that steroids contribute to a significant improvement in the 
prognosis in SLE, the effectiveness and usefulness of steroids are limited because of severe 
side effects, unresponsiveness and resistance to steroids. 
Now, new biological agents that target B cells, T-B cell interaction, co-stimulatory pathways, 
intracellular molecules, etc. are being developed and are going to begin to revolutionize 
nonspecific therapy to a more specific pathophysiological tharapy in SLE.  
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